“340B Drug Discount Program Faces Legal Gaps for Orphan Drugs with Multiple Uses, Pharmacis” — what this page in the network covers. A pharmacist is calling for legal updates to the 340B drug discount program, specifically regarding orphan-designated drugs that have multiple approved uses. The current regulations create ambiguity and potential compliance issues for covered entities and manufacturers. The pharmacist argues that the law has not kept pace with how these drugs are prescribed and used in practice. This gap can lead to disputes over discounts, affecting patient access and hospital budgets.
The issue matters because 340B savings help safety-net providers stretch resources, but unclear rules on orphan drugs with non-orphan indications create uncertainty. The pharmacist suggests that Congress or HRSA should clarify the rules to reflect real-world use. Without action, providers may face financial penalties or reduced access to critical medications. This listing links straight to the original page, where the content is available in full.